Sunshine Biopharma, Inc.
SBFM
$1.55
-$0.04-2.52%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -7.23% | 13.75% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -7.23% | 13.75% | |||
| Cost of Revenue | -5.09% | 16.75% | |||
| Gross Profit | -11.72% | 7.91% | |||
| SG&A Expenses | -24.37% | 29.06% | |||
| Depreciation & Amortization | -0.92% | 1.24% | |||
| Other Operating Expenses | 1.29% | 92.57% | |||
| Total Operating Expenses | -12.34% | 21.92% | |||
| Operating Income | 36.41% | -84.17% | |||
| Income Before Tax | 46.66% | -132.74% | |||
| Income Tax Expenses | 68.76% | -159.80% | |||
| Earnings from Continuing Operations | 45.33% | -80.18% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 45.33% | -80.18% | |||
| EBIT | 36.41% | -84.17% | |||
| EBITDA | 37.59% | -89.33% | |||
| EPS Basic | 56.50% | -6.17% | |||
| Normalized Basic EPS | 57.56% | -37.15% | |||
| EPS Diluted | 56.50% | -6.17% | |||
| Normalized Diluted EPS | 57.56% | -37.15% | |||
| Average Basic Shares Outstanding | 25.67% | 69.70% | |||
| Average Diluted Shares Outstanding | 25.67% | 69.70% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||